Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism EGFR modulators(Epidermal growth factor receptor erbB1 modulators) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR positive non-small cell lung cancer | Phase 2 | CN | 30 Mar 2023 | |
EGFR positive non-small cell lung cancer | Phase 2 | CN | 30 Mar 2023 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 1 | CN | 01 Aug 2023 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 1 | CN | 01 Aug 2023 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 06 Jan 2017 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 06 Jan 2017 |
CTR20190681 (ASCO2023) Manual | Phase 2 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 30 | aopcvmnxmg(kjtqpaghgd) = wbxqblrgjr zsakkhvtuq (hsjzdhiszh ) View more | Positive | 26 May 2023 | |
aopcvmnxmg(kjtqpaghgd) = glwldrzumu zsakkhvtuq (hsjzdhiszh ) View more |